Patents
Prevention of immunoreactivity by depleting or inhibiting antigen presenting cells
Patent Number: 7,288,255Graft versus host disease occurs after administration of allogeneic hematopoietic stem cell grafts. Essentially, graft versus host represents contaminating T cells from the graft attacking various tissues of the recipient. In some cases graft versus host disease is lethal. In fact, graft versus host disease is one of the largest causes of hematopoietic stem cell transplant associated...
Inventors: Shlomchik; Warren D. (Stratford, CT), Shlomchik; Mark Jay (Woodbridge, CT), Emerson; Stephen G. (Wayne, PA)
Assignee: Yale University (New Haven, CT)
Date of First Priority Issue: Wednesday November 12th, 1997
1 Comment
1 Comment
Growth factor therapy mobilization of stem cells into the peripheral blood
Patent Number: 7,288,521This patent covers a new way of mobilizing stem cells. Stem cell mobilization is usually performed on the donor of a hematopoietic graft so that instead of needing to puncture the donor bones to get bone marrow, the stem cells are "forced" into circulation by administration of a growth factor. Conventionally mobilization of stem cells is performed by systemic administration of G-CSF. In the...
Inventors: Franco; Wayne P. (Rocky Hill, CT)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday April 6th, 2000
Antibody to stem cell factor
Patent Number: 7,285,640This is a composition of matter patent on an antibody to stem cell factor. Since stem cell factor is involved in asthma, this is one of the proposed uses in the specification. Given that stem cell factor is also involved in numerous malignancies such as GIST, this patent may have many uses.
Inventors: Takeuchi; Toshihiko (Oakland, CA), Tomkinson; Adrian (Kensington, CA), Neben; Steven (Walnut Creek, CA)
Assignee: Bayer Corporation (Berkeley, CA)
Date of First Priority Issue: Monday December 17th, 2001
Medicament comprising HGF gene
Patent Number: 7,285,540Stimulation of angiogenesis is a method of treating numerous diseases associated with lack of oxygen, or ischemia. While numerous methods of inducing angiogenesis have been attempted (FGF injection, VEGF gene therapy, etc), there is still a need in the art for methods of reproducibly stimulating formation of new blood vessel development for conditions such as myocardial ischemia and peripheral...
Inventors: Morishita; Ryuichi (Osaka, JP), Ogihara; Toshio (Mino, JP), Nakamura; Toshikazu (Takatsuki, JP), Tomita; Tetsuya (Toyonaka, JP), Ochi; Takahiro (Kobe, JP)
Assignee: AnGes MG, Inc. (Osaka, JP)
Date of First Priority Issue: Thursday August 22nd, 1996
Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
Patent Number: 7,285,415The central nervous system is comprised of neurons and glia, with approximately ten times more glial cells than neurons. The function of glial cells is primarly to provide insulation(ie generation of myelin by oligodendrocytes), destroy pathogens/clear debris (microglia), provide structural support to neurons, as well as providing nutrients and growth factors. Astrocytes are the most...
Inventors: Keirstead; Hans S. (Irvine, CA), Nistor; Gabriel I. (Placentia, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Thursday July 11th, 2002
Isolation tool for viable c-kit expressing cells
Patent Number: 7,285,413CD-117, otherwise known as c-kit, is the receptor for stem cell factor, a cytokine involved in stimulating a variety of stem cells to cycle. Although c-kit was originally described on hematopoietic stem cells, this receptor has recently been found on numerous stem cell types ranging from liver oval cells to pancreatic duct stem cells. Additionally, c-kit has been found on tumor stem...
Inventors: Wouters; Mira Maria Willy (Ham, BE), Smans; Karine Alfonsine Astrid (Hove, BE), Vanderwinden; Jean-Marie (Brussels, BE)
Assignee: Janssen Pharmaceutica N.V. (BE)
Date of First Priority Issue: Wednesday December 12th, 2001
Methods of promoting the growth or differentiation of hematopoietic stem or progenitor cells by non-muscle type cofilin
Patent Number: 7,282,201One of the biggest payoffs in biotechnology has been development of therapeutics that modulate the hematopoietic stem cells. For example, agents such as EPO or G-CSF have become block-buster drugs for stimulation of erythropoiesis or granulopoiesis respectively. The current patent teaches a new way to stimulate hematopoiesis through administration of cofilin and sequences thereof. Cofilin...
Inventors: Miura; Kenju (Osaka, JP), Haruyama; Munetada (Hyogo, JP), Kodama; Shiho (Osaka, JP)
Assignee: Asubio Pharma Co., Ltd. (JP)
Date of First Priority Issue: Friday December 28th, 2001
Methods and compositions for directing cells to target organs
Patent Number: 7,282,222This patent covers the use of various carbohydrate presenting molecules for increasing amount of stem cell homing to tissue where stem cell migration is desired. Specific molecules that attract the stem cells which are covered include asialoorosomucoid and orosomucoid. This patent could be used to not only augment currented CD34 stem cell therapy efficacy but also in combination with stem...
Inventors: Phillips; Catherine (Amarillo, TX)
Assignee: The United States of America as Represented by the Department of Veterans Affairs (Washington, DC)
Date of First Priority Issue: Friday March 15th, 2002
Hepatocytes for therapy and drug screening made from embryonic stem cells
Patent Number: 7,282,366Medical advances of embryonic stem cells may indeed come initially from their use as research reagents before actually being developed as therapeutics. For example, few member of the public realize that practically all molecular biology was made possible by the mouse embryonic stem cell, which allowed for development of knockout and transgenic mice. In the current patent Geron covers methods...
Inventors: Rambhatla; Lakshmi (Redwood City, CA), Carpenter; Melissa K. (Castro Valley, CA)
Assignee: Geron Corporation (Menlo Park, CA)
Date of First Priority Issue: Thursday April 27th, 2000
22 Comments
22 Comments
Method of evaluating myelosuppressive state
Patent Number: 7,279,289In the spirit of Labcorp v Metabolite this patent covers methods of assessing a phenomena and based on this assessment intervening appropriately. If you read the case you will see where we are going with this. The patent covers the monitoring of various hematopoietic cytokines in order to assess myelosuppression. Cytokines...
Inventors: Blumenthal; Rosalyn D. (West Orange, NJ), Goldenberg; David M. (Mendham, NJ)
Assignee: Center for Molecular Medicine and Immunology (Belleville, NJ)
Date of First Priority Issue: Friday January 29th, 1999